Dengue Vaccine Market Forecasted to Reach USD $1.14 Billion by 2029 at 12.3% CAGR

 Claim 20% Off With Code ONLINE20 — Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights

 

 How Is the Dengue Vaccine Market Growth Forecast from 2025 to 2029?
 The dengue vaccine market size has grown exponentially in recent years. It will grow from $0.41 billion in 2024 to $0.51 billion in 2025 at a compound annual growth rate (CAGR) of 24.7%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.
 
 The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp
 
 Which Major Growth Drivers Will Influence the Dengue Vaccine Market by 2029?
 The rising number of dengue fever cases is expected to propel the growth of the dengue vaccine markets going forward. Dengue fever is a viral infection spread by Aedes aegypti mosquitoes, causing high fever, headaches, joint pain, and rashes. The rise in dengue fever cases is due to climate change, urbanization, inadequate mosquito control, and viral evolution. The dengue vaccine works by activating the immune system to identify and combat the dengue virus. It lessens infection severity and reduces the risk of severe complications, helping to decrease cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the rising number of dengue fever cases is driving the growth of the dengue vaccine market.
 
 What Are the Emerging Segments in the Dengue Vaccine Market?
 The dengue vaccine market covered in this report is segmented — 
 
 1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
 2) By Vaccine Phase: Phase I, Phase II, Phase III
 3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
 5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
 
 Subsegments:
 1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
 2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
 3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
 4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
 5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
 
 What Are the Key Industry Trends Transforming the Dengue Vaccine Market?
 Major companies operating in the dengue vaccine market are focused on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, to enhance protection against all four dengue virus serotypes in a single formulation. The dengue tetravalent vaccine provides immunity against all four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, received European Commission (EC) approval for QDENGA vaccine use in individuals from 4 years of age and older. It is a live-attenuated vaccine used in several dengue-endemic countries to protect against dengue fever. It uses a weakened dengue serotype two viruses as a genetic foundation for the other three serotypes. It is administered in two doses of 0.5 mL each at 0 and 3 months and targets individuals aged four years and older. A Phase 3 trial showed Qdenga has an efficacy of about 80.2% against dengue, with better results in preventing hospitalizations. Its protection lasts approximately 4.5 years, longer than many other vaccines.
 
 Who Are the Key Players Driving the Dengue Vaccine Market?
 Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd. 
 
 Get the full dengue vaccine market report here:
 https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report
 
 What Are the Regional Insights for the Dengue Vaccine Market Forecast?
 Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 LinkedIn: https://in.linkedin.com/company/the-business-research-company